Conclusions: Treatment options for advanced stage non-small cell lung cancer depend on: Histopathologic type, EGFR mutation, patient's physical condition and economy... Gefitinib is one of the effective target drugs in the first-line treatment for lung adenocarcinoma patients with EGFR gene mutations. It does improve the quality of patients' life and prolongs survival time with low and acceptable toxicity